Literature DB >> 24092926

Doubling down on PKC benefits allogeneic BMT.

Daniel H Fowler1.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 24092926      PMCID： PMC3790501          DOI： 10.1182/blood-2013-08-519900

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  9 in total

1.  PKC theta cooperates with PKC alpha in alloimmune responses of T cells in vivo.

Authors:  Thomas Gruber; Natascha Hermann-Kleiter; Christa Pfeifhofer-Obermair; Christina Lutz-Nicoladoni; Nikolaus Thuille; Thomas Letschka; Johannes Barsig; Monika Baudler; Jianping Li; Barbara Metzler; Barbara Nüsslein-Hildesheim; Juergen Wagner; Michael Leitges; Gottfried Baier
Journal:  Mol Immunol       Date:  2009-04-07       Impact factor: 4.407

2.  Overexpression of the autoimmunity-associated phosphatase PTPN22 promotes survival of antigen-stimulated CLL cells by selectively activating AKT.

Authors:  Roberto Negro; Stefania Gobessi; Pablo G Longo; Yantao He; Zhong-Yin Zhang; Luca Laurenti; Dimitar G Efremov
Journal:  Blood       Date:  2012-05-08       Impact factor: 22.113

3.  Sotrastaurin in calcineurin inhibitor-free regimen using everolimus in de novo kidney transplant recipients.

Authors:  H Tedesco-Silva; M M L Kho; A Hartmann; S Vitko; G Russ; L Rostaing; K Budde; J M Campistol; J Eris; I Krishnan; U Gopalakrishnan; J Klupp
Journal:  Am J Transplant       Date:  2013-05-09       Impact factor: 8.086

4.  Pharmacologic inhibition of PKCα and PKCθ prevents GVHD while preserving GVL activity in mice.

Authors:  Kelley M K Haarberg; Jun Li; Jessica Heinrichs; Dapeng Wang; Chen Liu; Crystina C Bronk; Kane Kaosaard; Alexander M Owyang; Sacha Holland; Esteban Masuda; Kin Tso; Bruce R Blazar; Claudio Anasetti; Amer A Beg; Xue-Zhong Yu
Journal:  Blood       Date:  2013-08-01       Impact factor: 22.113

5.  Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas.

Authors:  Tara L Naylor; Huaping Tang; Boris A Ratsch; Andreas Enns; Alice Loo; Liqing Chen; Peter Lenz; Nigel J Waters; Walter Schuler; Bernd Dörken; Yung-Mae Yao; Markus Warmuth; Georg Lenz; Frank Stegmeier
Journal:  Cancer Res       Date:  2011-02-15       Impact factor: 12.701

6.  Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.

Authors:  Xinqi Wu; Jingjing Li; Meijun Zhu; Jonathan A Fletcher; F Stephen Hodi
Journal:  Mol Cancer Ther       Date:  2012-05-31       Impact factor: 6.261

7.  Sotrastaurin (AEB071) alone and in combination with cyclosporine A prolongs survival times of non-human primate recipients of life-supporting kidney allografts.

Authors:  Marc Bigaud; Grazyna Wieczorek; Christian Beerli; Maxime Audet; Antoine Blancher; Christoph Heusser; Randall E Morris; Jürgen Wagner
Journal:  Transplantation       Date:  2012-01-27       Impact factor: 4.939

8.  PKCtheta is required for alloreactivity and GVHD but not for immune responses toward leukemia and infection in mice.

Authors:  Javier O Valenzuela; Cristina Iclozan; Mohammad S Hossain; Martin Prlic; Emily Hopewell; Crystina C Bronk; Junmei Wang; Esteban Celis; Robert W Engelman; Bruce R Blazar; Michael J Bevan; Edmund K Waller; Xue-Zhong Yu; Amer A Beg
Journal:  J Clin Invest       Date:  2009-11-09       Impact factor: 14.808

9.  Efficacy of sotrastaurin plus tacrolimus after de novo kidney transplantation: randomized, phase II trial results.

Authors:  G R Russ; H Tedesco-Silva; D R Kuypers; S Cohney; R M Langer; O Witzke; J Eris; C Sommerer; B von Zur-Mühlen; E S Woodle; J Gill; J Ng; J Klupp; L Chodoff; K Budde
Journal:  Am J Transplant       Date:  2013-05-13       Impact factor: 8.086
  9 in total
  1 in total

Review 1.  Role of calcium-dependent protein kinases in chronic myeloid leukemia: combined effects of PKC and BCR-ABL signaling on cellular alterations during leukemia development.

Authors:  André L Mencalha; Stephany Corrêa; Eliana Abdelhay
Journal:  Onco Targets Ther       Date:  2014-07-08       Impact factor: 4.147
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.